Wynn Capital LLC Acquires 305 Shares of Sanofi (NASDAQ:SNY)

Wynn Capital LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 4.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,431 shares of the company’s stock after acquiring an additional 305 shares during the period. Wynn Capital LLC’s holdings in Sanofi were worth $412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Patriot Financial Group Insurance Agency LLC grew its holdings in Sanofi by 1.0% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 24,114 shares of the company’s stock worth $1,337,000 after acquiring an additional 232 shares in the last quarter. UMB Bank n.a. grew its holdings in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock worth $62,000 after acquiring an additional 264 shares in the last quarter. Wedmont Private Capital grew its holdings in Sanofi by 5.9% during the 1st quarter. Wedmont Private Capital now owns 5,750 shares of the company’s stock worth $296,000 after acquiring an additional 321 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Sanofi by 7.9% during the first quarter. Sivia Capital Partners LLC now owns 6,404 shares of the company’s stock valued at $355,000 after buying an additional 467 shares during the last quarter. Finally, Stablepoint Partners LLC lifted its position in shares of Sanofi by 7.5% during the first quarter. Stablepoint Partners LLC now owns 26,945 shares of the company’s stock valued at $1,494,000 after buying an additional 1,882 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price target for the company. Finally, Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, three have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Sanofi has an average rating of “Buy” and a consensus target price of $61.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $50.47 on Friday. The firm has a market capitalization of $123.78 billion, a P/E ratio of 20.27, a PEG ratio of 1.01 and a beta of 0.50. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $51.71 and a 200 day moving average price of $51.98. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sanofi’s revenue was down 11.0% on a year-over-year basis. During the same period last year, the firm posted $1.78 EPS. Sell-side analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.